Replimune Group Stock Fundamentals
| REPL Stock | USD 13.62 0.45 3.20% |
Replimune Group fundamentals help investors to digest information that contributes to Replimune's financial success or failures. It also enables traders to predict the movement of Replimune Stock. The fundamental analysis module provides a way to measure Replimune's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Replimune stock.
At this time, Replimune's Total Other Income Expense Net is quite stable compared to the past year. Income Tax Expense is expected to rise to about 643.2 K this year, although the value of Depreciation And Amortization will most likely fall to about 2 M. Replimune | Select Account or Indicator |
Replimune Group Company Return On Equity Analysis
Replimune's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Replimune Return On Equity | -0.5 |
Most of Replimune's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Replimune Group is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Replimune Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Replimune Group has a Return On Equity of -0.5032. This is 97.9% lower than that of the Biotechnology sector and 98.62% lower than that of the Health Care industry. The return on equity for all United States stocks is 62.32% higher than that of the company.
Replimune Group Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Replimune's current stock value. Our valuation model uses many indicators to compare Replimune value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Replimune competition to find correlations between indicators driving Replimune's intrinsic value. More Info.Replimune Group is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Replimune's Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Replimune by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Replimune Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Replimune's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Replimune could also be used in its relative valuation, which is a method of valuing Replimune by comparing valuation metrics of similar companies.Replimune is currently under evaluation in return on equity category among its peers.
Replimune Current Valuation Drivers
We derive many important indicators used in calculating different scores of Replimune from analyzing Replimune's financial statements. These drivers represent accounts that assess Replimune's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Replimune's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 1.4B | 886.6M | 1.0B | 514.6M | 463.1M | 568.6M | |
| Enterprise Value | 1.3B | 813.5M | 942.2M | 516.0M | 464.4M | 527.2M |
Replimune ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Replimune's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Replimune's managers, analysts, and investors.Environmental | Governance | Social |
Replimune Fundamentals
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 726.83 M | ||||
| Shares Outstanding | 76.96 M | ||||
| Shares Owned By Insiders | 4.18 % | ||||
| Shares Owned By Institutions | 92.47 % | ||||
| Number Of Shares Shorted | 7.26 M | ||||
| Price To Book | 2.84 X | ||||
| EBITDA | (230.2 M) | ||||
| Net Income | (215.79 M) | ||||
| Cash And Equivalents | 395.08 M | ||||
| Cash Per Share | 8.01 X | ||||
| Total Debt | 75.87 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 19.79 X | ||||
| Book Value Per Share | 5.58 X | ||||
| Cash Flow From Operations | (185.47 M) | ||||
| Short Ratio | 8.98 X | ||||
| Earnings Per Share | (3.04) X | ||||
| Target Price | 20.0 | ||||
| Number Of Employees | 331 | ||||
| Beta | 1.19 | ||||
| Market Capitalization | 1.05 B | ||||
| Total Asset | 487.72 M | ||||
| Retained Earnings | (701.28 M) | ||||
| Working Capital | 393.23 M | ||||
| Net Asset | 487.72 M |
About Replimune Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Replimune Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Replimune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Replimune Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 35.2 M | 37 M | |
| Cost Of Revenue | 3.1 M | 2.2 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Replimune Piotroski F Score and Replimune Altman Z Score analysis. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.